Products refresher training webinar, with Sophie Tully BSc MSc, Wednesday 29th January In this training webinar, Education Manager Sophie Tully takes you through each of the therapeutic Igennus products and the key points for recommending them to clients to help refresh your memory, offering fresh research, understanding and clinical tools.

1. Igennus Product Refresher Webinar

2. What is inflammation?
• The normal response of a tissue to injury
• Triggered by a number of causes including infection, invading
pathogens (such as bacteria or viruses), trauma or
compromised blood flow
• Three defined phases:
- Initiation
- Resolution
- Termination

3. Inflammatory response
Resoleomics - the process of inflammation resolution
Eicosanoid switch
Stop signal
Pro-inflammatory reduced
LTB4
PGE2
Anti-inflammatory increased
Time
Initiation
Resolution
Termination

4. The role of diet in modulating inflammation
Many modern food types are new in regard to human evolution
Triggers from chronic altered diet and psycho-emotional stress negatively
influence the resolution step of the inflammatory response
Failure to resolve inflammation increases susceptibility to the development
of chronic, low-grade, inflammation-based diseases due to the constant
activation of both the HPA-axis and innate immune system
Bosma-den Boer MM, van Wetten ML, Pruimboom L: Chronic inflammatory diseases are stimulated by current lifestyle: how
diet, stress levels and medication prevent our body from recovering. Nutrition & metabolism 2012, 9:32.

6. The key to regulating inflammation is through the
modulation of eicosanoids:
⁻ pro-inflammatory eicosanoids drive the immune and inflammatory
processes
⁻ anti-inflammatory eicosanoids act to end the process through
resolution
Overproduction of pro-inflammatory products or reduced production
of anti-inflammatory products can result in continued production of
inflammatory products – the hallmark of silent inflammation

7. The role of lipid mediators
• Pro-inflammatory lipid
arachidonic acid (AA)
• Anti-inflammatory/pro-resolving lipids
dihomo-gamma-linolenic acid (DGLA)
eicosapentaenoic acid (EPA)
docosahexaenoic acid (DHA)
• AA and EPA are the significant eicosanoid precursors
• AA to EPA ratio is a direct biomarker of inflammatory status

8. •

9. AA to EPA ratio is a direct measure of inflammation
By modifying diet we can influence the ratio of pro-inflammatory (from AA)
to anti-inflammatory eicosanoids (from EPA)

10. Conditions associated with a high AA to EPA ratio
•
•
•
•
•
•
•
•
•
Depression
Bipolar disorder
Schizophrenia
Myalgic encephalomyelitis
Fibromyalgia
Chronic pain syndromes
Diabetes
Cardiovascular disease
Cancer
• Inflammatory disorders
• Inflammatory bowel disease:
(Crohn’s disease, ulcerative colitis)
• Neurodevelopmental disorders:
(autism, dyslexia, dyspraxia, ADHD)
• Alzheimer’s disease
• Huntington’s disease
• Skin conditions:
(eczema, psoriasis, dermatitis)

11. Shifting the balance
⁻ AA and EPA contents of cell membranes can be altered through consumption
of omega-3 EPA (marine products/marine oils)
⁻ Changing the fatty acid composition of cell membranes affects
• changes in membrane structure
• products involved in immune function and the inflammatory cascade
• cell signalling
• gene expression and cell cycle

12. EPA as a therapeutic agent
⁻ Cod liver oil benefits to health long established
⁻ Key protective and beneficial aspects are the essential fatty
acids: EPA and DHA
⁻ Only recently discovered, these two important EFAs have very
different roles within the body
⁻ EPA = anti-inflammatory, immune function, neuron and brain
function support
⁻ DHA = main structural fat for cells and brain development

13. EPA reduces the activity of AA in two ways
• EPA (but not DHA) is an inhibitor of the enzyme delta-5-desaturase
that produces AA
• EPA also competes with AA for the enzyme PLA2 necessary to release
AA from the membrane phospholipids
Therapeutically, fish oils are not all equal

14. Restore & Maintain® treatment protocol

15. Pharmepa®
Restore & Maintain™ anti-inflammatory protocol
Restore with
pure EPA
3-6 months
Introduce GLA
for long-term
maintenance

16. • Igennus is the only independent manufacturer
Step
of specialist Fatty 1: Restore UK. Based in
Acid in the
Cambridge the medical innovation hub for the
Pharmepa E-EPA 90 provides 1000 mg EPA with just
two easy-to-swallow capsules daily. This product
UK:
provides a loading dose of super strength EPA and is
Seven Seas for people whoPharma Germany with
Merck have never supplemented
ideal
or those who have taken a break from
Minami pure EPA EPA supplementation Canada
Atrium Pharma
omega-3
- Biocare
- Eskimo 3
- Equizen
Elder Pharma India
Bringwell Pharma Sweden
Vifor Pharma Swiss

17. • Igennus is theStep 2:independent manufacturer
only Maintain
Pharmepa E-EPA the UK. Based in
of specialist Fatty Acid in80 combines 80% ethyl-EPA
concentrate with GLA and
Cambridge the medicalprimrose oiltriterpenes from organic
innovation hub B5, D3the
for & E
virgin evening
and vitamins
UK:
This product balances and maintains the omega-6
Seven Seas omega-3 ratio and is suitableGermany use
Merck Pharma for long-term
to
Minami after supplementing PharmaEPA.
Atrium with pure Canada
Alternatively, long-term users of omega-3
Biocare supplements may Pharma and take step 2 as a
Elder skip step 1 India
Eskimo 3 maintenance supplement
Bringwell Pharma Sweden
- Equizen
Vifor Pharma Swiss

18. Pharmepa® Restore & Maintain™
Benefits summary
• Igennus is the only independent manufacturer
 Allows high concentrations of EPA to be achieved
 of specialist Fatty Acid in the UK. Based in
Maintains DHA levels:
• raises both the DHA levels DHA is needed) hub for the
CambridgeEPA andmedical(ifinnovationthus improving
index’
UK:'omega-3DHA loss from cell membranes
• protects








Enhances mitochondrial function
- Seven Seas
Merck Pharma Germany
Maintains cell integrity including neuronal systems
- Minami
Atrium Pharma Canada
Counteracts inflammation/oxidative stress
Powerful antidepressant
- Biocare
Elder Pharma India
Improves immune function
- Eskimo 3
Bringwell Pharma Sweden
Prevents the death of healthy cells
Induces 'programmed cell death' of damaged, genetically mutated cells
- Equizen
Vifor Pharma Swiss
Improves cardiovascular function

19. Vegan therapeutic alternative?

20. Echiomega
•• Igennus is theplantagineum
Derived from Echium only independent manufacturer
• of specialist Fatty Acid in the UK. Based in
Echium seed oil is a novel food approved
source of SDA and ALA
• Cambridge theEPA
SDA is the precursor to medical innovation hub for the
UK:
•
•
•
•
•
25-30% of SDA converts to EPA Merck Pharma Germany
- Seven Seas
5-8% of ALA
- Minami
Atrium Pharma Canada
Echiomega is naturally rich in SDA
SDA directly increases cellular EPA levels
- Biocare
Elder Pharma India
Echium seed oil provides standalone health benefits
- Eskimo 3
- Equizen
Bringwell Pharma Sweden
Vifor Pharma Swiss

21. Echiomega
• Igennus is the only independent manufacturer
 Provides the building blocks to restore optimum
of specialist Fatty Acid in the UK. Based in
omega-3 and omega-6 levels
 Favourable omega-6 tothe medical innovation hub for the
omega-3
Cambridgeand GLA ratio of 1:1.8
 Naturally high in SDA
UK:
 Vegetarian precursor to EPA





Supports immune function
Merck Pharma Germany
Naturally - Seven Seas
anti-inflammatory
Supports - Minami health
cardiovascular
Atrium Pharma Canada
Lowers triglycerides
Early studies show enhanced glycaemic control
- Biocare
Elder Pharma India
and reduced atherosclerosis in animal models
- Eskimo 3
- Equizen
Bringwell Pharma Sweden
Vifor Pharma Swiss

22. Nutritional co-therapeutics

23. Cardiovascular
Mood
health
disorders
Pharmepa®
Homocysteine
ControlTM
VESIsorb®
Ubiquinol
Pharmepa®
Homocysteine
ControlTM
Neurodevelopmental
disorders
Vegepa E-EPA 70
+ Chewables
NeurobalanceTM

24. Homocysteine ControlTM

25. Homocysteine ControlTM
• Igennus is the only independent manufacturer
folic acid, vitamin B6 and vitamin B12
of specialist Fatty Acid in the UK. Based in
formulated to prevent and the medical innovation hub for the
Cambridge reduce elevated
plasma homocysteine
UK:
slow-release delivery system
- Seven Seas
Merck Pharma Germany
most bioavailable forms of each ingredient
- Minami
Atrium Pharma Canada
ensures optimal blood plasma levels are
- Biocare
Elder Pharma India
maintained throughout the day
- Eskimo 3
Bringwell Pharma Sweden
- Equizen
Vifor Pharma Swiss

26. Homocysteine ControlTM
• Igennus is the only independent manufacturer
of specialist Fatty Acid in the UK. Based in
 Highly bioavailable
Lowers homocysteine levels
Cambridge the medical innovation hubnutrients
for the
 Easy-to-swallow tablets
Supports cardiovascular function
 Split-dosing for optimal bioavailability
UK:
Supports healthy mood
 Sustained-release tablets for



 Supports methylation pathways
 Supports neurotransmitter
metabolism
 Supports red blood cell formation
 Supports neurological function
 Supports DNA and protein
synthesis
- Seven Seas
- Minami
- Biocare
- Eskimo 3
- Equizen
enhanced absorption &
Merck Pharma Germanyoptimal
tissue distribution
 Offers benefits for cardiovascular
Atrium Pharmabrain function and mood
Canada
health,
balance
Elder Pharma India
Bringwell Pharma Sweden
Vifor Pharma Swiss

27. Homocysteine clinical levels 0.0 – 15 mmol
Desirable
Optimal
Critical
0
6.0
9.0
15+

28. Role and benefits of a healthy methylation cycle
 Neurotransmitter production:
o Mood
o Memory
o Learning
o Gut function
 Antioxidant activity:
o Increased glutathione production
o Reduced free radical production
 Cardioprotection:
o Reduced risk of cardiovascular disease and
stroke
 Detoxification:
o Improved liver function
o Increased energy
o Improved sleep
 Neuroprotection
 Improves cell signalling
 Anti-inflammatory
 Normal cell cycle
 Reduced risk of bone loss and fracture
 Improved fertility
 Anti-ageing

29. Therapeutic application for Homocysteine ControlTM
 Cardiovascular disease
o Heart attack
o Stroke
o Vascular disease
o Atherosclerosis
 Mood disorders
o Depression
o Schizophrenia
o Bipolar syndrome
 Neurodegenerative diseases
o Huntington’s disease
o Parkinson’s disease
o Alzheimer’s disease
 Neuromuscular diseases
o Muscular dystrophy
o Multiple sclerosis
 Migraine
 Cell cycle control
 Diabetes
 Liver disorders
 Thyroid disease/low thyroid function
 Infertility
 Pregnancy complications
 Macular degeneration
 Chronic fatigue syndrome

30. Homocysteine ControlTM
Nutritional information
Serving size: 1 tablet
Amount per tablet
% RDA
8 mg
570%
Vitamin B12 (as methylcobalamin)
300 µg
12,000%
Folic acid
300 µg
150%
Vitamin B6 (as pyridoxal-5-phosphate)
Ingredients
Bulking agent: calcium carbonate; emulsifier: microcrystalline cellulose; thickener:
hydroxypropyl methylcellulose; vitamin B6 (pyridoxal-5-phosphate); anti-caking agents:
magnesium stearate, stearic acid; folic acid; vitamin B12 (methylcobalamin); glycerol.

31. Neurobalance
TM

32. NeurobalanceTM
• magnesium, zinc and vitamin B6
•
•
• Igennus is the only independent manufacturer
formulated to aid in normalFatty Acid in the UK. Based in
of specialist neurotransmitter
production and function
Cambridge the medical innovation hub for the
scientifically formulated supplement
UK:
• synergistic benefits to optimise the functioning of the
- Seven Seas
Merck Pharma
nervous system
•
•
Germany
- Minami
Atrium Pharma Canada
slow-release delivery system ensures optimal blood
- Biocare
Elder the
plasma nutrient levels are maintained throughout Pharma India
day
- Eskimo 3
Bringwell Pharma Sweden
most bioavailable forms of each ingredient
- Equizen
Vifor Pharma Swiss

33. NeurobalanceTM






• Igennus is the only independent manufacturer
of specialist Fatty Acid in the UK. Based in
Cambridge
Supports neurotransmitter the medical innovation hub for the
 Highly bioavailable nutrients
metabolism
 Synergistic relationship between Mg
UK:
Supports neurological function
and B6
Supports hormone balance
Supports immune function
Supports DNA and protein synthesis
Aids in the production of sleep
modulators
 Supports a healthy mood
 Anti-anxiety benefits
- Seven Seas
- Minami
- Biocare
- Eskimo 3
- Equizen
 Easy-to-swallow tablets
 Split-dosing for optimal bioavailability
 Sustained-release tablets for enhanced
absorption & optimal tissue distribution
 Offers benefits for brain function and
mood balance
Merck Pharma Germany
Atrium Pharma Canada
Elder Pharma India
Bringwell Pharma Sweden
Vifor Pharma Swiss

35. Neurotransmitter
Functions
Dopamine
Movement, memory, pleasurable, reward, behaviour,
cognition, attention, inhibition of prolactin
production, sleep, mood, learning
Serotonin
Mood, appetite, sleep, memory, learning, body
temperature, pain
Melatonin
Libido, sleep, immune function
Norepinephrine
‘Fight or flight’ response, attentiveness, mood,
mental arousal, emotions, sleep, dreaming, learning
Epinephrine
‘Fight or flight’ response, mental focus, attention
GABA
Muscle tone, sleep, anxiety modulator

36. Therapeutic application for Neurobalance

o
o
o
o

o
o
o
Neurodevelopmental disorders
Attention-deficit hyperactivity-disorder (ADHD)
Autistic spectrum disorders (ASD)
Dyspraxia
Dyslexia
Mood disorders
Depression
Schizophrenia
Bipolar syndrome

o
o
o
Neurodegenerative diseases
Huntington’s disease
Parkinson’s disease
Alzheimer’s disease
 Women’s health
o Premenstrual syndrome
(PMS)
o Menopausal symptoms

37. NeurobalanceTM
Nutritional information
Serving size: 2 tablets
Amount per tablet
% RDA
Zinc methionine
14 mg
140 %
Magnesium (elemental)*
60 mg
16 %
Vitamin B6 (pyridoxal-5-phosphate)
10 mg
714%
* from 376 mg magnesium citrate
Ingredients
Magnesium citrate; bulking agent: calcium carbonate; emulsifier: microcrystalline
cellulose; zinc methionine; vitamin B6 (pyridoxal-5-phosphate); thickener: hydroxypropyl
methylcellulose; anti-caking agents: stearic acid, silicon dioxide, magnesium stearate.

38. VESIsorb® Ubiquinol-QH

39. VESIsorb® Ubiquinol-QH
• VESIsorb® Ubiquinol-QH
•
•
• Igennus is the only independent manufacturer
most bioavailable source of the activated form of
of specialist Fatty Acid in the UK. Based in
coenzyme Q10 (CoQ10)
Cambridge the medical innovation hub for the
patented VESIsorb® delivery system provides
UK:
colloidal, highly solubilised ubiquinol
- Seven the water layer barrier in the gut
Merck Pharma Germany
• passes easily throughSeas
and into the bloodstream
- Minami
Atrium Pharma Canada
• unprecedented absorption
- Biocare
•
•
Elder Pharma India
- Eskimo 3
Bringwell Pharma Sweden
optimal blood CoQ10 levels
- Equizen
Vifor Pharma Swiss
1 a day provides therapeutic, sustained action

40. VESIsorb® Ubiquinol-QH
• Igennus is the only independent manufacturer
of specialist Fatty Acid in the UK. Based in
 Energy production
 Patented VESIsorb® delivery system
Cambridge the medical innovation hub for the
 Antioxidant activity
 Mimics natural intestinal transport
UK:
 Cardioprotection
 easily absorbed into the bloodstream for




Neuroprotection
Anti-inflammatory
Promotes thermogenesis
Cellular communication & gene
expression
 Supports organ metabolism
 Supports normal cell cycle
- Seven Seas
- Minami
- Biocare
- Eskimo 3
- Equizen
optimal tissue distribution
Pre-digested solubilised ubiquinol for faster
absorption
Reaches therapeutic plasma concentrations
Sustained action
Unprecedented bioavailability
1-a-day dosing

Merck Pharma Germany
Atrium Pharma Canada

Elder 
Pharma India


Bringwell Pharma Sweden
Vifor Pharma Swiss

41. Coenzyme Q10
• CoQ10 is a powerful, fat-soluble, vitamin-like substance
• Two main functions:
• Energy production – cellular respiration
• Antioxidant/antioxidant recycling
•
Two main forms
• Ubiquinone – oxidised form
• Ubiquinol – reduced form
• 96% of CoQ10 within the body is in the form of ubiquinol
• Ubiquinol is the active form of CoQ10

42. CoQ10 production and intake
• Endogenous CoQ10 synthesis is a complex multi-step process
• Tissue CoQ10 levels generally peak around the age of 20-30 and decline
with age
• The conversion of ubiquinone to ubiquinol also declines with age
• Majority of dietary CoQ10 is in the form of ubiquinone
• Found in foods such as fish, organ meats and germ of whole grains, the
average diet is estimated to provide approximately 10 mg/day of CoQ10

43. Ubiquinol deficiency alters mitochondria function and lowers
antioxidant status, leading to increased free radical generation
Inflammation
Lungs
Free radical
damage and
oxidative stress
Skin
Ageing
Cardiovascular
Brain
Immunity

44. Acetyl-CoA
HMG-CoA synthase
HMG-CoA
HMG-CoA reductase
inhibitors (statins)
HMG-CoA reductase
Mevalonate
Cholesterol
Coenzyme Q10
(ubiquinone)

45. • Absorption occurs in the small intestine directly into the lymphatic
system followed by absorption into the bloodstream
• Absorption is generally poor (large lipophilic molecule) and fat soluble
molecules must cross the ‘unstirred’ water layer for effective uptake
• ~60% of oral supplements may be excreted via the faeces
• High variability with absorption depending on the dosage form
• Highest bioavailability when taken with lipid-containing food

46. VESIsorb® technology
• The aqueous diffusion layer or 'unstirred' water layer adjacent to the intestinal
membrane has long been regarded as a potential barrier for intestinal absorption
of compounds, especially large fat-soluble molecules
• The task of naturally formed bile salt-mixed micelles, having a size <10 nm, is to
transport the lipophilic molecules through the aqueous environment of the
gastrointestinal tract and across the unstirred water layer to the absorptive
epithelium
• VESIsorb® is a novel delivery technology that mimics this natural absorption
process to improve bioavailability of large lipophilic molecules

47. Plasma CoQ10 (mg/mL)
7.5
7
6.5
6
5.5
5
4.5
4
3.5
3
2.5
2
1.5
1
0.5
0
Cmax
VESIsorb® delivered CoQ10 is
absorbed FASTER, reaching
concentrations that are STRONGER
and stay in the body LONGER than
generic delivery methods
Therapeutic level
VESIsorb®
Tmax
Oil-based
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Time (hours)
120mg single dose of VESIsorb® delivered CoQ10 reaches therapeutic levels within 2 hours, reaching maximum
blood plasma levels (6.89 mg/mL) (Cmax) within around 4 hours (Tmax)
In contrast, 120mg single dose of oil-based CoQ10 reaches maximum blood plasma levels (2.44 mg/mL) within 5
hours and fails to achieve therapeutic levels
VESIsorb® increases the bioavailability of CoQ10 by 622%

48. VESIsorb® Ubiquinol-QH
Nutritional information
Serving size: 1 capsule
Ubiquinol (Kaneka QH
TM
Amount per capsule
– activated coenzyme Q10)
Vitamin E ( α-tocopherol)
100 mg
6.7 mg α-TE*
*56% EU RDA
Ingredients
Ubiquinol activated coenzyme Q10 (Kaneka-QH™); capsule shell (emulsifier: gelatine;
glycerol: colour: caramel); medium chain triglycerides; emulsifiers: non-ionic surfactant,
polyglycerol fatty acid esters; antioxidant: vitamin E.

49. Therapeutic applications for VESIsorb® Ubiquinol-QH
 Cardiovascular disease
o Cardiomyopathy
o Congestive heart failure
o Angina
o Arrhythmias
o Hypertension
o Atherosclerosis
 Neurodegenerative diseases
o Huntington’s disease
o Parkinson’s disease
o Alzheimer’s disease
 Neuromuscular diseases
 Chronic fatigue syndrome












Statin-associated myopathy
Mitochondrial disease
Muscular dystrophy
Chronic fatigue conditions
Diabetes
Cell cycle regulation
Chronic obstructive pulmonary disease
Migraine
Immune disorders
HIV/AIDS
Periodontal disease
Male infertility

50. • Igennus is the www.igennus.com
only independent manufacturer
01223 421434
of specialist Fatty Acid in the UK. Based in
info@igennus.com
Cambridge the medical innovation hub for the
UK:
Sophie Tully
Nutrition education manager
- Seven Seas sophiet@igennus.com
Merck Pharma Germany
- Minami education@igennus.com
Atrium Pharma Canada
07908683174
- Biocare
Elder Pharma India
- Eskimo 3
Bringwell Pharma Sweden
- Equizen
Vifor Pharma Swiss